Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON , UK, April 19, 2021 /EINPresswire.com/ Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
Mergers and acquisitions are a major clinical decision support system market trend. In January 2019, Qiagen, a Germany based provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research acquired N-of-One for an undisclosed amount. N-of-One is a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The acquisition of N-of-One will enable QIAGEN to significantly expand its decision-support s
April 19, 2021
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). The results could help scientists better understand disease origin and progression in patients. The paper is published online today in the journal
Molecular Cell.
“Our findings are very exciting in the field of both autoimmune disease and cancer, as they illustrate how pathogenic cells can ‘mis-use’ machinery from related cell types to cause disease and protect themselves from elimination,” said Markus Müschen, MD, PhD, Director of the Center of Molecular and Cellular Oncology and Arthur H. and Isabel Bunker Professor of Medicine (Hematology) at Yale Cancer Center, and senior author of the study.
Incyte and MorphoSys AG: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
Respiratory tract infection
These are not all the possible side effects of MONJUVI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:
Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.